Illinois Municipal Retirement Fund lifted its stake in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 36.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 114,142 shares of the company’s stock after buying an additional 30,368 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.07% of Alkermes worth $4,625,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in ALKS. Baird Financial Group Inc. purchased a new position in Alkermes in the second quarter worth approximately $2,791,000. S&CO Inc. acquired a new position in Alkermes during the 2nd quarter worth approximately $12,824,000. Quantinno Capital Management LP grew its holdings in Alkermes by 131.1% during the 1st quarter. Quantinno Capital Management LP now owns 44,932 shares of the company’s stock worth $1,589,000 after acquiring an additional 25,492 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Alkermes during the 2nd quarter worth approximately $2,479,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Alkermes in the 1st quarter valued at approximately $855,000. 95.21% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, EVP David Gaffin sold 2,035 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the transaction, the executive vice president owned 219,353 shares in the company, valued at approximately $10,127,528.01. This represents a 0.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig Hopkinson sold 9,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total transaction of $422,910.00. Following the completion of the transaction, the executive vice president owned 65,389 shares of the company’s stock, valued at approximately $3,072,629.11. The trade was a 12.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 15,103 shares of company stock worth $697,973. 4.59% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on ALKS shares. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective (up from $43.00) on shares of Alkermes in a report on Tuesday, July 28th. Wells Fargo & Company lifted their price objective on shares of Alkermes from $65.00 to $68.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Alkermes in a research note on Wednesday, November 4th. Needham & Company LLC reissued a “buy” rating and issued a $62.00 target price on shares of Alkermes in a report on Monday, September 21st. Finally, Truist Financial started coverage on Alkermes in a report on Friday, October 16th. They issued a “buy” rating and a $55.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $55.73.
View Our Latest Stock Report on Alkermes
Alkermes Price Performance
ALKS stock opened at $47.03 on Monday. The business has a 50 day moving average price of $43.67 and a 200 day moving average price of $41.13. The stock has a market cap of $7.90 billion, a price-to-earnings ratio of -2,350.32 and a beta of 0.32. Alkermes plc has a fifty-two week low of $27.00 and a fifty-two week high of $55.67. The company has a quick ratio of 2.02, a current ratio of 2.42 and a debt-to-equity ratio of 0.79.
Alkermes (NASDAQ:ALKS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.17. The firm had revenue of $480.13 million during the quarter, compared to the consensus estimate of $463.48 million. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The firm’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.49 earnings per share. Equities research analysts anticipate that Alkermes plc will post -0.52 earnings per share for the current fiscal year.
About Alkermes
Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.
Featured Articles
- Five stocks we like better than Alkermes
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
